10/584035

IAP20 Rec'd PCT/PTO 22 JUN 2006

Express Mail Label No.: EV716305168US

Date of Deposit: June 22, 2006

DOCKET NO.: L0461.70154US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

KOPS and CLEVELAND

Int'l Application No.

PCT/US2003/041189

Int'l Filing Date

22 December 2003 (22.12.2003)

Title

METHODS AND COMPOSITIONS FOR

REGULATING CELL CYCLE CHECKPOINTS

Mail Stop PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the enclosed Search Report from corresponding International Application No. PCT/US2003/041189, mailed July 6, 2004, and the International Preliminary Examination Report, mailed 14 March 2006.

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

1043772.1

10/584035

IAP20 Rec'd PCT/PTQ 22 JUN 2006

Applicant: KOPS and CLEVELAND

- 3 -

An early and favorable action is hereby requested.

Respectfully submitted,

By:

John R. Van Amsterdam

Reg. No. 40,212

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: L0461.70154US00

Date: June 22, 2006

xx 06/22/2006

					IAP20 Rec'd PC	T/P10 2	3 JUN SUUD		
FORM PTO-	1449/A an	d R (modified	1 PT()/SR/()8)		APPLICATIÓN NO.: 52003/041189		ATTY. DOCKET NO.: L0461.70154US00		
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT					INT'L FILING DATE: 22 December 2003		CONFIRMATION NO 4n Co 35		
				AFFLICA	APPLICANT: KOPS and CLEVELAND				
Sheet 1 of 1			1	GROUP	GROUP ART UNIT: Unknown EXA		R: Unknown		
	_								
		111	Potent Docum		PATENT DOCUMENTS		T D. CD. Lilian	• •	
Examiner's Initials #	Cite	No. Number		Kind	Kind Name of Patentee or Applicant of Cited of Cited		of Cited Document		
							MM-DD-Y	YYY	
	A1			Al	Bennett et al.	Bennett et al. 05-27-200			
· _									
				+			<u> </u>		
									
				FOREI	GN PATENT DOCUMENTS				
Examiner's Initials #	Cite	Forei	ign Patent Docu	ment	Name of Patentee or Applicant of Cited Kind Code Name of Patentee or Applicant of Cited Document Cited Document MM-DD-YYYY			Translation (Y/N)	
	No.	Office/ Country	Number						
				+					
				+					
		-			N PATENT LITERATURE DOCU				
Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Translation (Y/N)							
	C1	GORBSKY et al., "Microinjection of Antibody to Mad2 Protein into Mammalian Cells in Mitosis Induces Premature Anaphase," <i>Journal of Cell Biology</i> , June 1, 1998, vol. 141, No. 5, pp. 1193-1205 (see Figs. 1-11).							
	C2	CHAN et al., "Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC," <i>Journal of Cell Biology</i> , September 6, 1999, Vol. 146, No. 5, pp. 941-945 (see Figs. 1-7).							
EXAMINER:		 *	·		DATE CONSIDERED) <u>. </u>			

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

^{*}EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.